AU Patent

AU2008302744A1 — Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Assigned to Ambit Bioscience Corp · Expires 2009-03-26 · 17y expired

What this patent protects

Patent listed against quizartinib-dihydrochloride.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2008302744A1
Jurisdiction: AU
Classification: —
Expires: 2009-03-26
Drug substance claim: No
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.